Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules

British Journal of Radiology

Volumn 81, Issue 967, 2008, Pages 549-563

  Wyatt, R M ^a   Jones, B J ^a   Dale, R G ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; POISSON DISTRIBUTION; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SQUAMOUS CELL CARCINOMA; THERAPY DELAY; TUMOR DIAGNOSIS; TUMOR GROWTH;

BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; EARLY DIAGNOSIS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TIME FACTORS; TREATMENT OUTCOME;

EID: 46849101017     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/94471640     Document Type: Article

References (92)

1. Wyatt RM, Beddoe AH, Dale RG. The effects of delays in radiotherapy treatment on tumour control. Phys Med Biol 2003;48:139-55.
2. Dale RG, Hendry JH, Jones B, Robertson AG, Deehan C, Sinclair JA. Practical methods for compensating for missed treatment days in radiotherapy, with particular reference to head and neck schedules. Clin Oncol 2002;14:382-93.
3. Slevin NJ, Hendry JH, Roberts SA, Agren-Cronqvist A. The effects of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy. Radiother Oncol 1992;24:215-20.
4. Saarilahti K, Kajanti M, Lehtonen H, Hamalainen T, Joensuu H. Repopulation during radical radiotherapy for T1 glottic cancer. Radiother Oncol 1998;47:155-9.
5. Brouha XDR, Op De Coul B, Terhaard CHJ, Hordijk GJ. Does waiting time for radiotherapy affect local control of T1N0M0 glottic laryngeal carcinoma? Clin Otolaryngol 2000;25:215-8.
6. Stuschke M, Thames H. Fractionation sensitivities and dose-control relations of head and neck carcinomas: analysis of the randomised hyperfractionation trials. Radiother Oncol 1999;51:113-21.
7. Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997;44:123-36.
8. Fowler JF, Harari PM. Confirmation of improved loco-regional control with altered fractionation in head and neck cancer. Int J Radiat Oncol Biol Phys 2000;48:3-6.
9. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, et al. A radiation therapy oncology group (RTOG) phase III randomised study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
10. Skladowski K, Maciejewski B, Golen M, Tarnawski R, Slosarek K, Suwinski R, et al. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial. Int J Radiat Oncol Biol Phys 2006;66:706-13.
11. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003;362:933-40.
12. Horiot JC, Bontemps P, van den Bogaert W, Le Fur R, van den Weijngaert D, Bolla M, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997;44:111-21.
13. Dobrowsky W, Naude J. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol 2000;57:119-24.
14. Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M. Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall time. Int J Radiat Oncol Biol Phys 2006;64:77-82.
15. Fowler JF. Is there an optimum overall time for head and neck radiotherapy? A review, with new modelling. Clin Oncol 2007;19:8-22.
16. Barton MB, Morgan G, Smee R, Tiver KW, Hamilton C, Gebski V. Does waiting time affect the outcome of larynx cancer treated by radiotherapy? Radiother Oncol 1997;44: 137-41.
17. Fortin A, Bairati I, Albert M, Moore L, Allard J, Couture C. Effect of treatment delay on outcome in patients with early-stage head-and-neck carcinoma receiving radiotherapy. Int J Radiat Oncol Biol Phys 2002;52:929-36.
18. Muriel VP, Tejada MRG, Luna del Castillo JD. Time-dose response relationships in postoperatively irradiated patients with head and neck squamous cell carcinomas. Radiother Oncol 2001;60:137-45.
19. Suwinski R, Sowa A, Rutkowski T, Wydmanski J, Tarnawski R, Maciejewski B. Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. Int J Radiat Oncol Biol Phys 2003;56:339-412.
20. Awwad HK, Lotayef M, Shouman T, Begg AC, Wilson G, Bentzen SM, et al. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. Br J Cancer 2002;86: 517-23.
21. Ang KK, Trotti A, Brown BW, Garden AS, Fode RL, Morrison WH, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head and neck cancer. In J Radiat Oncol Biol Phys 2001;51:571-8.
22. Trotti A, Klotch D, Endicott J, Ridley M, Cantor A. Postoperative accelerated radiotherapy in high-risk squamous cell carcinoma of the head and neck: long-term results of a prospective trial. Head Neck 1998;20:119-23.
23. Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ. Does delay in starting treatment affect the outcomes of radiotherapy? J Clin Oncol 2003;21:555-63.
24. Schiff PB, Harrison L, Strong EW, Fass DE, Shah JP, Spiro R, et al. Impact of the time interval between surgery and postoperative radiation therapy on locoregional control in advanced head and neck cancer. J Surg Oncol 1990;43:203-8.
25. Al-Dweri FMO, Guirado D, Lallena AM, Pedraza V. Effect on tumour control of time interval between surgery and postoperative radiotherapy: an empirical approach using Monte Carlo simulation. Phys Med Biol 2004;49:2827-39.
26. Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L, et al. Randomised trial of breast irradiation schedules after lumpectomy for women with lymph-node negative breast cancer. J Natl Cancer Inst 2002;94:1143-50.
27. Yamada Y, Ackerman I, Franssen E, MacKenzie R, Thomas G. Does the dose fractionation schedule influence local control of adjuvant radiotherapy for early stage breast cancer? Int J Radiat Oncol Biol Phys 1999;44:99-104.
28. Olivotto IA, Kim-Sing C, Bajdik CD, Trevisan CH, Ludgate CM, Weir LM, et al. Effect of acetylsalycilic acid on radiation and cosmetic results after conservation surgery for early breast cancer: a randomised trial. Radiother Oncol 1996;41:1-6.
29. Bartelink H, Horiot J-C, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001; 345:1378-87.
30. Romestaing P, Lehingue Y, Carrie C, Coquard R, Montbarbon X, Ardiet JM, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomised clinical trial in Lyon, France. J Clin Oncol 1997;15:963-8.
31. Roger OJ, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 2006;7:467-71.
32. START trial management group. Standardisation of breast radiotherapy (START) trial. Clin Oncol 1999;11:145-7.
33. Slotman BJ, Meyer OW, Njo KH, Karim AB. [Radiotherapy following breast-conserving surgery: more local recurrences after long delay]. Ned Tijdschr Geneeskd 1995;139:2427-32.
34. Benk V, Joseph L, Fortin P, Zhang G, Belisle P, Levinton C, et al. Effect of delay in initiating radiotherapy for patients with early stage breast cancer. Clin Oncol 2004;16:6-11.
35. Nixon AJ, Recht A, Neuberg D, Connolly JL. The relation between surgery-radiotherapy interval and treatment outcome in patients treated with breast-conserving surgery and radiation therapy without systemic therapy. Int J Radiat Oncol Biol Phys 1994;30:12-17.
36. Vujovic O, Yu E, Cherian A, Dar RA, Stitt L, Perara F. Eleven-year follow-up results in the delay of breast irradiation after conservative breast surgery in node-negative breast cancer patients. Int J Radiat Oncol Biol Phys 2006;64:760-4.
37. Recht A, Come SE, Henderson C, Gelman RS, Silver B, Hayes DF, et al. The sequencing of chemotherapy and radiotherapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996;334:1356-61.
38. Hanks GE, Hanlon AL Epstein B, Horwitz EM. Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 2002;54:427-35.
39. Fowler J, Chappell R, Ritter M. Is α/β for prostate tumours really low? Int J Radiat Oncol Biol Phys 2001;50:1021-31.
40. Wang JZ, Guerrero M, Li XA. How low is the α/β for prostate cancer? Int J Radiat Oncol Biol Phys 2003;55: 194-203.
41. Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 2005;44:65-76.
42. Hiratsuka J, Yoshimasa J, Yoshida K, Nagase N, Fujisawa M, Imajo Y. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localised prostate cancer. Int J Radiat Oncol Biol Phys 2004;59:684-90.
43. Pellizzon ACA, Nadalin W, Salvajoli JV, Fogaroli RC, Novaes PERS, Maia MAC, et al. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Radiother Oncol 2003;66:167-72.
44. Martinez AA, Gustafson G, Gonzalez J, Armour E, Mitchell C, Edmundson G, et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavourable prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:316-27.
45. Neumann T, Mark R, Anderson PJ, Nair M. Interstitial high dose rate (HDR) brachytherapy + IMRT vs. HDR monotherapy for early stage prostate cancer. J Clin Oncol 2006;24:14606.
46. Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004;171:1098-104.
47. Livsey JE, Cowan RA, Wylie JP, Swindell R, Read G, Khoo VS, et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys 2003;57:1254-9.
48. Lukka H, Hayter C, Julian JA, Morris WJ, Gospodarowicz M, Levine M, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005;23:6132-8.
49. Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 2005;63:1463-8.
50. Berit LM, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5Gy in five fractions for localised disease. First clinical trial results. Int J Radiat Oncol Biol Phys 2007;67:1099-105.
51. Widmark A, et al. Phase III study of HYPO-fractionated radiotherapy (HYPORT) of intermediate risk prostate cancer. Proceedings of the 2nd Acta Oncol Symposium; 2004 May 22-26; Faroe Islands.
52. Mott JH, Livsey JE, Logue JP. Development of a simultaneous boost IMRT class solution for a hypofractionated prostate cancer protocol. Br J Radiol. 2004;77:377-86.
53. Webb S. Optimum parameters in a model for tumour-control probability including interpatient heterogeneity. Phys Med Biol 1994;39:1895-914.
54. Peters LJ, Goepfert H, Ang KK, Byers RM, Maor MH, Guillamondegui O, et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1993;26:3-11.
55. Amer AM, Mott J, Mackay RI, Willimas PC, Livsey J, Logue JP, et al. Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2003;56: 199-207.
56. Jones B, Dale RG. Inclusion of molecular biotherapies with radical radiotherapy: modeling of combined modality treatment schedules. Int J Radiat Oncol Biol Phys 1999;45:1025-34.
57. Steele G, editor. Basic clinical radiobology, 2nd edition. New York, USA: Oxford University Press, 1997.
58. Begg A, Haustermans K, Hart A, Dische S, Saunders M, Zackrisson B, et al. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol 1999;50:13-23.
59. Hoyer M, Jorgensen K, Bundgaard T, Johansen LV, Bentzen SM, Overgaard M, et al. Lack of predictive value of potential doubling time and iododeoxyuridine labelling index in radiotherapy of squamous cell carcinoma of the head and neck. Radiother Oncol 1998;46:147-55.
60. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095-101.
61. Lee WR, Hanks GE, Corn BW, Schultheiss TE. Observations of pre-treatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy. Int J Radiat Oncol Biol Phys 1995;31:21-4.
62. Haustermans K, Fowler JF. A comment on proliferation rates in human prostate cancer. Int J Radiat Oncol Biol Phys 2000;48:303.
63. Johnson A. The timing of treatment in breast cancer: gaps and delays in treatment can be harmful. Breast Cancer Res Treat 2000;60:201.
64. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131-46.
65. Roberts SA, Hendry JH. A realistic closed-form radiobiological model of clinical tumour-control data incorporating intertumor heterogeneity. Int J Radiat Oncol Biol Phys 1998;41:689-99.
66. Roberts SA, Hendry JH. Time factors in larynx tumour radiotherapy: lag times and intertumour heterogeneity in clinical datasets from four centres. Int J Radiat Oncol Biol Phys 1999;45:1247-57.
67. Tarnawski R, Fowler J, Skladowski K, Swierniak A, Suwinski R, Maciejewski B, et al. How fast is repopulation of tumour cells during the treatment gap? Int J Radiat Oncol Biol Phys 2002;54:229-36.
68. Demicheli R. Tumour dormancy: findings and hypotheses from clinical research on breast cancer. Semin Cancer Biology 2001;11:297-06.
69. Braunschweiger PG, Schiffer LM, Betancourt S. Tumour cell proliferation and sequential chemotherapy after partial tumour resection in C3H/HeJ mammary tumours. Breast Cancer Res Treat 1982;2:323-9.
70. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumour. Cancer Res 1979;39:3861-5.
71. pot? Radiother Oncol 1998;46: 157-67.
72. Fenwick JD. Predicting the radiation control probability of heterogeneous tumour ensembles: data analysis and parameter estimation using a closed-form expression. Phys Med Biol 1996;43:2159-78.
73. King CR, Fowler JF. Yes, the α/β ratio for prostate cancer is low or "methinks the lady doth protest too much.....about a low α/β that is". Int J Radiat Oncol Biol Phys 2002;54:626-8.
74. Horiot JC, Le Fur R, N'Guyen T, Chenal C, Schraub S, Alfonsi S, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomised trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992;25:231-41.
75. Sanchiz F, Milla A, Torner J, Bonrt F, Artola N, Carreno L, et al. Single fraction per day vs two fractions per day vs radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 1990;19:1347-50.
76. Cummings B, O'Sullivan B, Keane T, et al. 5-year results of 4-week/twice daily radiation schedule - the Toronto trial. Radiother Oncol 2000;56:S8.
77. Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in sqamous cell head and neck cancer: A GORTEC trial. J Clin Oncol 2006;24:2873-8.
78. Poulsen MG, Denham JW, Peters LJ, Lamb DS, Spry NA, Hindley A, et al. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study. Radiother Oncol 2001;60:113-22.
79. Sanguineti G, Richetti A, Bignardi M, Corvo' R, Gabriele P, Sormani MP, et al. Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study. Int J Radiat Oncol Biol Phys 2005;61:762-71.
80. Shah N, Saunders MI, Dische S. A pilot study of postoperative CHART and CHARTWEL in head and neck cancer. Clin Oncol 2000;12:392-6.
81. Whelan TJ, Clark RM, Levine MN, Willan A, McCulloch P, Lipa M, et al. The effect of delay in initiating radiotherapy post-lumpectomy on local breast recurrence. Int J Radiat Oncol Biol Phys 1996;36(Suppl):280.
82. Peeters STH, Heemsbergen WD, Koper PCM, van Putten WLJ, Slot A, Dielwart MFH, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomised phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol 2006;25:1990-6.
83. Dearnley DP, Hall E, Lawrence D, Huddart EA, Eeles R, Nutting CM, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005;92:488-98.
84. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: results of the MD Anderson phase III randomised trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
85. Yeoh EEK, Fraser RJ, McGowan RE, Botten RJ, Di Matteo AC, Roos DE, et al. Evidence for efficacy without increased toxcicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. Int J Radiat Oncol Biol Phys 2003;55:943-55.
86. Gowda RV, Henk JM, Mais KL, Sykes AJ, Swindell R, Slevin NJ. Three weeks radiotherapy for T1 glottic cancer: the Christie and Royal Marsden Hospital experience. Radiother Oncol 2003;68:205-22.
87. Peteriet DG, Rogers D, Govern F, Coleman N, Osburn CH, Howard SP, et al. Increasing access to clinical cancer trials and emerging technologies for minority populations: the native American Project. J Clin Oncol 2004;22:4452-4.
88. Yoshoika Y, Nose T, Yoshida K, Inoue T, Yamazaki H, Tanaka E, et al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 2000;48:675-81.
89. Martin T, Baltas D, Kurek R, Roddiger S, Kontova M, Anagnostopoulos G, et al. 3-D conformal HDR brachytherapy as monotherapy for localised prostate cancer. Strahlentherapie und Onkologie 2004;180:225-32.
90. Pollack A, Hanlon AL, Horwitz SJ, Feigenberg SJ, Konski AA, Movsas B, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation trial. Int J Radiat Oncol Biol Phys 2006;64:518-26.
91. Khoo V, Norman A, Syndikus R, Huddart C, Eeles R, Horwich A, et al. Randomized pilot study of conventional or hypofractionated high dose intensity modulated prostate radiotherapy (CHHIP)-acute toxicity report. ASCO 2005 Prostate Cancer Symposium; 2005 February 17-19; Orlando, FL. Abstract no 89. Available from: www.asco.org/ASCO/ abstracts.
92. Ritter MA, Chappell RJ, Tome WA, Kupelian PA. A multiinstitutional phase I/II trial of dose-per fraction escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2005;63(Suppl 1):S124.